Qdenga

Qdenga (TAK-003) is a live-attenuated tetravalent dengue vaccine developed by Takeda. It is constructed using a live-attenuated dengue serotype 2 (DENV-2) virus as the genetic backbone, which provides the non-structural proteins for all four vaccine components. The structural proteins (envelope and pre-membrane) for serotypes 1, 3, and 4 are substituted into the DENV-2 backbone, while the DENV-2 component is the original attenuated strain. This design allows the vaccine to replicate and induce both neutralizing antibodies and T-cell mediated immune responses against all four dengue serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). It is indicated for the prevention of dengue fever in individuals aged 4 years and older. Prince of Songkla University has specifically investigated the immunogenicity of intradermal administration of this vaccine compared to the standard subcutaneous route in healthy volunteers.

Brand names

Qdenga

Other names

Dengue tetravalent vaccine (live, attenuated)Takeda dengue vaccine